Cathay Innovation

Tracked participation in 4 Atlas companies, with 3 explicitly attributed leads.

4portfolio companies

9round participations

3lead positions

$1.1Bled round total

Conviction

Most recent leads

The latest rounds this investor is sourced as leading, newest first.

Mar 2026AMI LabsSeed (official launch / first disclosed round)$1Bat $3B valuation Jan 2025BioptimusFollow-on injection (details not fully specified publicly)$41MJan 2024NablaSeries B (initial close)$24M

Capital activity

Portfolio

CompanyLatest valuationFirst → latestRoundsRoleAttributed partner

OOwkinScienceOwkin is a privately held AI company building “agentic” biological AI products for drug discovery, clinical…$1Bvaluation$635.2MraisedRecent roundsTotal disclosed (company press kit aggregate) · null$304.1M · Bpifrance Large Ventures, Bristol-Myers Squibb +10Spin-out financing: Waiv (formerly Owkin Dx) · Mar 2026$33M · led by Alpha Intelligence Capital, OTB VenturesStrategic collaboration with Bristol Myers Squibb (incl. Series B-1 equity investment) · Jun 2022$80M · led by Bristol Myers SquibbOwkin—Jan 2018 → null4 roundsParticipant—

ALAMI Labs$3BMar 2026 → Mar 20261 round1 led—

NNabla—Jan 2024 → Jun 20252 rounds1 led—

BBioptimus—Feb 2024 → Jan 20252 rounds1 ledJacky Abitbol

DateCompanyRoundRaisedValuationRoleEvidence

nullOOwkinScienceOwkin is a privately held AI company building “agentic” biological AI products for drug discovery, clinical…$1Bvaluation$635.2MraisedRecent roundsTotal disclosed (company press kit aggregate) · null$304.1M · Bpifrance Large Ventures, Bristol-Myers Squibb +10Spin-out financing: Waiv (formerly Owkin Dx) · Mar 2026$33M · led by Alpha Intelligence Capital, OTB VenturesStrategic collaboration with Bristol Myers Squibb (incl. Series B-1 equity investment) · Jun 2022$80M · led by Bristol Myers SquibbOwkinTotal disclosed (company press kit aggregate)$304.1M—Participant

Source ↗

Mar 10, 2026ALAMI LabsSeed (official launch / first disclosed round)$1B$3BLead

Source ↗+1 ↗

Jun 17, 2025NNablaSeries C$70M—Participant

Source ↗

Jan 14, 2025BBioptimusFollow-on injection (details not fully specified publicly)$41M—Lead · Jacky Abitbol

Source ↗

Feb 20, 2024BBioptimusSeed$35M—Participant

Source ↗

Jan 05, 2024NNablaSeries B (initial close)$24M—Lead

Source ↗

May 07, 2020OOwkinScienceOwkin is a privately held AI company building “agentic” biological AI products for drug discovery, clinical…$1Bvaluation$635.2MraisedRecent roundsTotal disclosed (company press kit aggregate) · null$304.1M · Bpifrance Large Ventures, Bristol-Myers Squibb +10Spin-out financing: Waiv (formerly Owkin Dx) · Mar 2026$33M · led by Alpha Intelligence Capital, OTB VenturesStrategic collaboration with Bristol Myers Squibb (incl. Series B-1 equity investment) · Jun 2022$80M · led by Bristol Myers SquibbOwkinSeries A extension / fresh financing$25M—Participant

Source ↗+1 ↗

Mar 07, 2019OOwkinScienceOwkin is a privately held AI company building “agentic” biological AI products for drug discovery, clinical…$1Bvaluation$635.2MraisedRecent roundsTotal disclosed (company press kit aggregate) · null$304.1M · Bpifrance Large Ventures, Bristol-Myers Squibb +10Spin-out financing: Waiv (formerly Owkin Dx) · Mar 2026$33M · led by Alpha Intelligence Capital, OTB VenturesStrategic collaboration with Bristol Myers Squibb (incl. Series B-1 equity investment) · Jun 2022$80M · led by Bristol Myers SquibbOwkinSeries A (venture round / extension)——Participant

Source ↗

Jan 16, 2018OOwkinScienceOwkin is a privately held AI company building “agentic” biological AI products for drug discovery, clinical…$1Bvaluation$635.2MraisedRecent roundsTotal disclosed (company press kit aggregate) · null$304.1M · Bpifrance Large Ventures, Bristol-Myers Squibb +10Spin-out financing: Waiv (formerly Owkin Dx) · Mar 2026$33M · led by Alpha Intelligence Capital, OTB VenturesStrategic collaboration with Bristol Myers Squibb (incl. Series B-1 equity investment) · Jun 2022$80M · led by Bristol Myers SquibbOwkinSeries A$11M—Participant

Source ↗

DateCompanyRoundRaisedValuationRoleEvidence

Mar 10, 2026ALAMI LabsSeed (official launch / first disclosed round)$1B$3BLead

Source ↗+1 ↗

Source ↗

Jun 17, 2025NNablaSeries C$70M—Participant

Source ↗

Jan 14, 2025BBioptimusFollow-on injection (details not fully specified publicly)$41M—Lead · Jacky Abitbol

Source ↗

Feb 20, 2024BBioptimusSeed$35M—Participant

Source ↗

Source ↗+1 ↗

Jan 05, 2024NNablaSeries B (initial close)$24M—Lead

Source ↗